Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

NCT03333343 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

105

Enrollment

INDUSTRY

Sponsor class

Conditions

EGFR-mutant Non-small Cell Lung Cancer

Interventions

DRUG: EGF816
DRUG: trametinib
DRUG: ribociclib
DRUG: LXH254
DRUG: INC280
DRUG: gefitinib

Sponsor

Novartis Pharmaceuticals